DM Healthcare Investment

Rege Nephro Announces Joint Research Agreement with ABI Co Ltd and Nikkiso Co Ltd

January 12, 2021

Rege Nephro Co., Ltd. (Headquarters: Sakyo-ku, Kyoto, Representative Director: Toshihiro Ishikiriyama, hereinafter “Rege Nephro”) has signed a joint research agreement with ABI Co., Ltd. (Headquarters: Nagareyama City, Chiba Prefecture, President: Norio Owada, hereinafter “ABI”) .

The purpose of this joint research agreement is to develop a manufacturing process for non- clinical and clinical trial samples for cell therapy using renal progenitor cells, and ABI will promote development of cryopreservation process.

ABI has developed the “CAS (Cells Alive System) engine” as the world’s first “device that saves cells” that was originally developed, and is actively jointly developing it with companies, universities, research institutes, etc. In particular, the development in the medical field is remarkable, and various results have been achieved such as practical application of periodontal ligament to transplantation medicine, establishment of cryopreservation technology for human iPS cell-derived neural progenitor cells, and establishment of transplantation regeneration therapy alternative to living-donor liver transplantation. Furthermore, by applying this technology to the food field and attaching the CAS engine to an existing quick freezer, we have succeeded in developing technology that restores the state to “the same as raw materials.”

By concluding a joint research agreement with ABI, Rege Nephro will promote the development speed by proceeding with the development of manufacturing processes for differentiation induction, expansion culture, and cryopreservation in parallel, and is eventually aiming for leading to integrated production. Rege Nephro will promote its business under the mission of improving the quality of life (QOL) of patients suffering from kidney disease and contributing to society.

Rege Nephro Co., Ltd. (Headquarters: Sakyo-ku, Kyoto, Representative Director: Toshihiro Ishikiriyama, hereinafter “Rege Nephro”) has signed a joint research agreement with NIKKISO Co., Ltd. (Headquarters: Shibuya-ku, Tokyo, President: Toshihiko Kai, hereinafter “NIKKISO”) .

The purpose of this joint research agreement is to develop a manufacturing process for non-clinical and clinical trial samples for cell therapy using renal progenitor cells, and NIKKISO will mainly promote the development of expanded culture processes.

In this joint research, NIKKISO will develop a system for culturing a large amount of renal progenitor cells using the technologies that Nikkiso has cultivated in its existing business, such as fluid control technology and component measurement technology.

By concluding a joint research agreement with NIKKISO, Rege Nephro will promote the development speed by proceeding with the development of manufacturing processes for differentiation induction, expansion culture, and cryopreservation in parallel, and is eventually aiming for leading to integrated production. Rege Nephro will promote its business under the mission of improving the quality of life (QOL) of patients suffering from kidney disease and contributing to society.